Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Other Non-Current Liabilities for 17 consecutive years, with $297.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 41.69% year-over-year to $297.7 million; the trailing twelve-month figure through Jun 2026 stood at $297.7 million (up 41.69% YoY), and the FY2025 full-year result was $219.7 million, up 32.19% from the prior year.
• Other Non-Current Liabilities improved to $297.7 million in Q2 2026 per NBIX's latest filing, from $260.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $297.7 million in Q2 2026 and bottomed at $17.1 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $129.3 million across 5 years, with a median of $127.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities decreased 7.51% in 2022, then surged 301.17% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $29.7 million in 2022, then jumped by 257.91% to $106.3 million in 2023, then jumped by 56.35% to $166.2 million in 2024, then surged by 32.19% to $219.7 million in 2025, then soared by 35.5% to $297.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $297.7 million, $260.9 million, and $219.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.